Central serous chorioretinopathy: update on pathophysiology and treatment

Surv Ophthalmol. Mar-Apr 2013;58(2):103-26. doi: 10.1016/j.survophthal.2012.07.004.

Abstract

Recent technological advances--new pathophysiological insights, new imaging techniques for diagnosis and management, and new treatments--have led to an improved understanding of central serous chorioretinopathy (CSC). The primary role of the choroid has become more widely accepted with widespread use of indocyanine green angiography. Optical coherence tomography (OCT), and particularly enhanced depth imaging OCT, demonstrate a thickened and engorged choroid. Adaptive optics, fundus autofluorescence, multifocal electroretinography, microperimetry, and contrast sensitivity testing reveal that patients with even a mild course suffer previously undetected anatomic and functional loss. Although focal laser and photodynamic therapy are the current standard of care for persistent subretinal fluid in CSC, they are not appropriate in all cases, and the optimal timing of intervention remains unclear.

Publication types

  • Review

MeSH terms

  • Central Serous Chorioretinopathy / diagnosis
  • Central Serous Chorioretinopathy / physiopathology*
  • Central Serous Chorioretinopathy / therapy*
  • Coloring Agents
  • Fluorescein Angiography
  • Humans
  • Indocyanine Green
  • Laser Coagulation
  • Photochemotherapy
  • Tomography, Optical Coherence
  • Visual Field Tests

Substances

  • Coloring Agents
  • Indocyanine Green